Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Sodium Glycididazole Reduces Chemoradiotherapy-related Adverse Reactions During Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
40 participants
May 29, 2024
INTERVENTIONAL
Conditions
Summary
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Eligibility
Inclusion Criteria4
- Patients must have histologically or cytologically confirmed non-small cell lung cancer.
- Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy.
- ECOG PS 0-2
- Adequate organ and bone marrow function.
Exclusion Criteria7
- History of previous radiotherapy.
- The previous immune-related pneumonitis ≥ grade 2.
- Local lesions require surgery.
- History of another primary malignancy.
- History of active primary immunodeficiency.
- Histological findings showed mixed small cell lung cancer and non-small cell lung cancer.
- For any unmitigated toxicity during pre-study chemoradiotherapy.
Interventions
Sodium glycididazole is intravenously infused at a dose of 800mg at 60 min before radiotherapy and used on Mondays, Wednesdays and Fridays during radiotherapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06667622